nodes	percent_of_prediction	percent_of_DWPC	metapath
Vardenafil—CYP3A5—Tamoxifen—pancreatic cancer	0.0831	0.186	CbGbCtD
Vardenafil—CYP3A5—Erlotinib—pancreatic cancer	0.0707	0.159	CbGbCtD
Vardenafil—CYP3A5—Irinotecan—pancreatic cancer	0.0638	0.143	CbGbCtD
Vardenafil—CYP3A5—Docetaxel—pancreatic cancer	0.0468	0.105	CbGbCtD
Vardenafil—CYP3A5—Sunitinib—pancreatic cancer	0.0466	0.104	CbGbCtD
Vardenafil—CYP3A4—Tamoxifen—pancreatic cancer	0.0324	0.0727	CbGbCtD
Vardenafil—CYP3A4—Erlotinib—pancreatic cancer	0.0276	0.0618	CbGbCtD
Vardenafil—CYP3A4—Irinotecan—pancreatic cancer	0.0249	0.0558	CbGbCtD
Vardenafil—CYP3A4—Docetaxel—pancreatic cancer	0.0182	0.0409	CbGbCtD
Vardenafil—CYP3A4—Sunitinib—pancreatic cancer	0.0182	0.0407	CbGbCtD
Vardenafil—CYP3A4—Doxorubicin—pancreatic cancer	0.0136	0.0305	CbGbCtD
Vardenafil—Mental disorder—Docetaxel—pancreatic cancer	0.000367	0.000968	CcSEcCtD
Vardenafil—Somnolence—Fluorouracil—pancreatic cancer	0.000366	0.000967	CcSEcCtD
Vardenafil—Face oedema—Doxorubicin—pancreatic cancer	0.000364	0.000963	CcSEcCtD
Vardenafil—Erythema—Docetaxel—pancreatic cancer	0.000364	0.000962	CcSEcCtD
Vardenafil—Dyspepsia—Fluorouracil—pancreatic cancer	0.000363	0.000958	CcSEcCtD
Vardenafil—Nausea—Tamoxifen—pancreatic cancer	0.000362	0.000956	CcSEcCtD
Vardenafil—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.000362	0.000955	CcSEcCtD
Vardenafil—Gastritis—Epirubicin—pancreatic cancer	0.000361	0.000954	CcSEcCtD
Vardenafil—Alanine aminotransferase increased—Epirubicin—pancreatic cancer	0.00036	0.00095	CcSEcCtD
Vardenafil—Pain—Gemcitabine—pancreatic cancer	0.000358	0.000946	CcSEcCtD
Vardenafil—Nausea—Erlotinib—pancreatic cancer	0.000358	0.000946	CcSEcCtD
Vardenafil—Diarrhoea—Sunitinib—pancreatic cancer	0.000357	0.000944	CcSEcCtD
Vardenafil—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.000356	0.000939	CcSEcCtD
Vardenafil—Feeling abnormal—Irinotecan—pancreatic cancer	0.000354	0.000936	CcSEcCtD
Vardenafil—Blood creatinine increased—Doxorubicin—pancreatic cancer	0.000354	0.000934	CcSEcCtD
Vardenafil—Influenza—Epirubicin—pancreatic cancer	0.000353	0.000931	CcSEcCtD
Vardenafil—Dysphagia—Epirubicin—pancreatic cancer	0.000353	0.000931	CcSEcCtD
Vardenafil—Back pain—Docetaxel—pancreatic cancer	0.000352	0.000931	CcSEcCtD
Vardenafil—Pain—Fluorouracil—pancreatic cancer	0.000352	0.00093	CcSEcCtD
Vardenafil—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.000352	0.000929	CcSEcCtD
Vardenafil—Muscle spasms—Docetaxel—pancreatic cancer	0.00035	0.000925	CcSEcCtD
Vardenafil—Liver function test abnormal—Doxorubicin—pancreatic cancer	0.000348	0.000921	CcSEcCtD
Vardenafil—Dizziness—Sunitinib—pancreatic cancer	0.000345	0.000912	CcSEcCtD
Vardenafil—Feeling abnormal—Gemcitabine—pancreatic cancer	0.000345	0.000912	CcSEcCtD
Vardenafil—Orthostatic hypotension—Doxorubicin—pancreatic cancer	0.000345	0.000911	CcSEcCtD
Vardenafil—Abdominal pain upper—Doxorubicin—pancreatic cancer	0.000345	0.000911	CcSEcCtD
Vardenafil—Angina pectoris—Epirubicin—pancreatic cancer	0.000343	0.000907	CcSEcCtD
Vardenafil—Breast disorder—Doxorubicin—pancreatic cancer	0.000341	0.000901	CcSEcCtD
Vardenafil—Abdominal pain—Irinotecan—pancreatic cancer	0.00034	0.000898	CcSEcCtD
Vardenafil—Aspartate aminotransferase increased—Doxorubicin—pancreatic cancer	0.00034	0.000898	CcSEcCtD
Vardenafil—Feeling abnormal—Fluorouracil—pancreatic cancer	0.000339	0.000897	CcSEcCtD
Vardenafil—Gastritis—Doxorubicin—pancreatic cancer	0.000334	0.000882	CcSEcCtD
Vardenafil—Alanine aminotransferase increased—Doxorubicin—pancreatic cancer	0.000333	0.000879	CcSEcCtD
Vardenafil—Vomiting—Sunitinib—pancreatic cancer	0.000332	0.000877	CcSEcCtD
Vardenafil—Rash—Sunitinib—pancreatic cancer	0.000329	0.00087	CcSEcCtD
Vardenafil—Dermatitis—Sunitinib—pancreatic cancer	0.000329	0.000869	CcSEcCtD
Vardenafil—Headache—Sunitinib—pancreatic cancer	0.000327	0.000864	CcSEcCtD
Vardenafil—Syncope—Docetaxel—pancreatic cancer	0.000327	0.000863	CcSEcCtD
Vardenafil—Dysphagia—Doxorubicin—pancreatic cancer	0.000326	0.000862	CcSEcCtD
Vardenafil—Influenza—Doxorubicin—pancreatic cancer	0.000326	0.000862	CcSEcCtD
Vardenafil—Palpitations—Docetaxel—pancreatic cancer	0.000322	0.00085	CcSEcCtD
Vardenafil—Photosensitivity reaction—Epirubicin—pancreatic cancer	0.000322	0.00085	CcSEcCtD
Vardenafil—Loss of consciousness—Docetaxel—pancreatic cancer	0.00032	0.000846	CcSEcCtD
Vardenafil—Angina pectoris—Doxorubicin—pancreatic cancer	0.000318	0.000839	CcSEcCtD
Vardenafil—Hypersensitivity—Irinotecan—pancreatic cancer	0.000317	0.000837	CcSEcCtD
Vardenafil—Convulsion—Docetaxel—pancreatic cancer	0.000316	0.000834	CcSEcCtD
Vardenafil—Infestation NOS—Epirubicin—pancreatic cancer	0.000314	0.00083	CcSEcCtD
Vardenafil—Infestation—Epirubicin—pancreatic cancer	0.000314	0.00083	CcSEcCtD
Vardenafil—Myalgia—Docetaxel—pancreatic cancer	0.00031	0.000819	CcSEcCtD
Vardenafil—Arthralgia—Docetaxel—pancreatic cancer	0.00031	0.000819	CcSEcCtD
Vardenafil—Chest pain—Docetaxel—pancreatic cancer	0.00031	0.000819	CcSEcCtD
Vardenafil—Nausea—Sunitinib—pancreatic cancer	0.00031	0.000819	CcSEcCtD
Vardenafil—Asthenia—Irinotecan—pancreatic cancer	0.000309	0.000815	CcSEcCtD
Vardenafil—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.000308	0.000814	CcSEcCtD
Vardenafil—Conjunctivitis—Epirubicin—pancreatic cancer	0.000306	0.000807	CcSEcCtD
Vardenafil—Hypersensitivity—Fluorouracil—pancreatic cancer	0.000303	0.000802	CcSEcCtD
Vardenafil—Dry mouth—Docetaxel—pancreatic cancer	0.000303	0.000801	CcSEcCtD
Vardenafil—Sweating—Epirubicin—pancreatic cancer	0.000301	0.000796	CcSEcCtD
Vardenafil—Asthenia—Gemcitabine—pancreatic cancer	0.000301	0.000794	CcSEcCtD
Vardenafil—Haematuria—Epirubicin—pancreatic cancer	0.0003	0.000792	CcSEcCtD
Vardenafil—Photosensitivity reaction—Doxorubicin—pancreatic cancer	0.000298	0.000787	CcSEcCtD
Vardenafil—Hepatobiliary disease—Epirubicin—pancreatic cancer	0.000297	0.000785	CcSEcCtD
Vardenafil—Anaphylactic shock—Docetaxel—pancreatic cancer	0.000297	0.000785	CcSEcCtD
Vardenafil—Epistaxis—Epirubicin—pancreatic cancer	0.000297	0.000783	CcSEcCtD
Vardenafil—Pruritus—Gemcitabine—pancreatic cancer	0.000296	0.000783	CcSEcCtD
Vardenafil—Infection—Docetaxel—pancreatic cancer	0.000295	0.00078	CcSEcCtD
Vardenafil—Sinusitis—Epirubicin—pancreatic cancer	0.000295	0.000779	CcSEcCtD
Vardenafil—Diarrhoea—Irinotecan—pancreatic cancer	0.000294	0.000777	CcSEcCtD
Vardenafil—Shock—Docetaxel—pancreatic cancer	0.000292	0.000773	CcSEcCtD
Vardenafil—Nervous system disorder—Docetaxel—pancreatic cancer	0.000292	0.00077	CcSEcCtD
Vardenafil—Pruritus—Fluorouracil—pancreatic cancer	0.000291	0.00077	CcSEcCtD
Vardenafil—Infestation NOS—Doxorubicin—pancreatic cancer	0.000291	0.000768	CcSEcCtD
Vardenafil—Infestation—Doxorubicin—pancreatic cancer	0.000291	0.000768	CcSEcCtD
Vardenafil—Tachycardia—Docetaxel—pancreatic cancer	0.00029	0.000766	CcSEcCtD
Vardenafil—Skin disorder—Docetaxel—pancreatic cancer	0.000289	0.000763	CcSEcCtD
Vardenafil—Diarrhoea—Gemcitabine—pancreatic cancer	0.000287	0.000757	CcSEcCtD
Vardenafil—Dizziness—Irinotecan—pancreatic cancer	0.000284	0.000751	CcSEcCtD
Vardenafil—Haemoglobin—Epirubicin—pancreatic cancer	0.000284	0.000749	CcSEcCtD
Vardenafil—Rhinitis—Epirubicin—pancreatic cancer	0.000283	0.000747	CcSEcCtD
Vardenafil—Conjunctivitis—Doxorubicin—pancreatic cancer	0.000283	0.000747	CcSEcCtD
Vardenafil—Haemorrhage—Epirubicin—pancreatic cancer	0.000282	0.000746	CcSEcCtD
Vardenafil—Diarrhoea—Fluorouracil—pancreatic cancer	0.000282	0.000744	CcSEcCtD
Vardenafil—Hypoaesthesia—Epirubicin—pancreatic cancer	0.000281	0.000742	CcSEcCtD
Vardenafil—Pharyngitis—Epirubicin—pancreatic cancer	0.00028	0.00074	CcSEcCtD
Vardenafil—Sweating—Doxorubicin—pancreatic cancer	0.000279	0.000737	CcSEcCtD
Vardenafil—Urinary tract disorder—Epirubicin—pancreatic cancer	0.000279	0.000736	CcSEcCtD
Vardenafil—Hypotension—Docetaxel—pancreatic cancer	0.000278	0.000734	CcSEcCtD
Vardenafil—Haematuria—Doxorubicin—pancreatic cancer	0.000277	0.000733	CcSEcCtD
Vardenafil—Connective tissue disorder—Epirubicin—pancreatic cancer	0.000277	0.000733	CcSEcCtD
Vardenafil—Urethral disorder—Epirubicin—pancreatic cancer	0.000277	0.000731	CcSEcCtD
Vardenafil—Hepatobiliary disease—Doxorubicin—pancreatic cancer	0.000275	0.000727	CcSEcCtD
Vardenafil—Epistaxis—Doxorubicin—pancreatic cancer	0.000274	0.000725	CcSEcCtD
Vardenafil—Vomiting—Irinotecan—pancreatic cancer	0.000273	0.000722	CcSEcCtD
Vardenafil—Sinusitis—Doxorubicin—pancreatic cancer	0.000273	0.000721	CcSEcCtD
Vardenafil—Dizziness—Fluorouracil—pancreatic cancer	0.000272	0.000719	CcSEcCtD
Vardenafil—Visual impairment—Epirubicin—pancreatic cancer	0.000272	0.000718	CcSEcCtD
Vardenafil—Rash—Irinotecan—pancreatic cancer	0.000271	0.000716	CcSEcCtD
Vardenafil—Dermatitis—Irinotecan—pancreatic cancer	0.000271	0.000716	CcSEcCtD
Vardenafil—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.000271	0.000715	CcSEcCtD
Vardenafil—Headache—Irinotecan—pancreatic cancer	0.000269	0.000712	CcSEcCtD
Vardenafil—Insomnia—Docetaxel—pancreatic cancer	0.000269	0.00071	CcSEcCtD
Vardenafil—Paraesthesia—Docetaxel—pancreatic cancer	0.000267	0.000705	CcSEcCtD
Vardenafil—Vomiting—Gemcitabine—pancreatic cancer	0.000266	0.000704	CcSEcCtD
Vardenafil—Dyspnoea—Docetaxel—pancreatic cancer	0.000265	0.0007	CcSEcCtD
Vardenafil—Somnolence—Docetaxel—pancreatic cancer	0.000264	0.000698	CcSEcCtD
Vardenafil—Rash—Gemcitabine—pancreatic cancer	0.000264	0.000698	CcSEcCtD
Vardenafil—Dermatitis—Gemcitabine—pancreatic cancer	0.000264	0.000697	CcSEcCtD
Vardenafil—Eye disorder—Epirubicin—pancreatic cancer	0.000264	0.000697	CcSEcCtD
Vardenafil—Tinnitus—Epirubicin—pancreatic cancer	0.000263	0.000695	CcSEcCtD
Vardenafil—Haemoglobin—Doxorubicin—pancreatic cancer	0.000262	0.000693	CcSEcCtD
Vardenafil—Headache—Gemcitabine—pancreatic cancer	0.000262	0.000693	CcSEcCtD
Vardenafil—Flushing—Epirubicin—pancreatic cancer	0.000262	0.000692	CcSEcCtD
Vardenafil—Cardiac disorder—Epirubicin—pancreatic cancer	0.000262	0.000692	CcSEcCtD
Vardenafil—Vomiting—Fluorouracil—pancreatic cancer	0.000262	0.000692	CcSEcCtD
Vardenafil—Rhinitis—Doxorubicin—pancreatic cancer	0.000262	0.000692	CcSEcCtD
Vardenafil—Dyspepsia—Docetaxel—pancreatic cancer	0.000262	0.000691	CcSEcCtD
Vardenafil—Haemorrhage—Doxorubicin—pancreatic cancer	0.000261	0.00069	CcSEcCtD
Vardenafil—Hypoaesthesia—Doxorubicin—pancreatic cancer	0.00026	0.000686	CcSEcCtD
Vardenafil—Rash—Fluorouracil—pancreatic cancer	0.00026	0.000686	CcSEcCtD
Vardenafil—Dermatitis—Fluorouracil—pancreatic cancer	0.000259	0.000685	CcSEcCtD
Vardenafil—Pharyngitis—Doxorubicin—pancreatic cancer	0.000259	0.000685	CcSEcCtD
Vardenafil—Headache—Fluorouracil—pancreatic cancer	0.000258	0.000682	CcSEcCtD
Vardenafil—Urinary tract disorder—Doxorubicin—pancreatic cancer	0.000258	0.000681	CcSEcCtD
Vardenafil—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.000257	0.000678	CcSEcCtD
Vardenafil—Connective tissue disorder—Doxorubicin—pancreatic cancer	0.000257	0.000678	CcSEcCtD
Vardenafil—Angiopathy—Epirubicin—pancreatic cancer	0.000256	0.000676	CcSEcCtD
Vardenafil—Urethral disorder—Doxorubicin—pancreatic cancer	0.000256	0.000676	CcSEcCtD
Vardenafil—Nausea—Irinotecan—pancreatic cancer	0.000255	0.000675	CcSEcCtD
Vardenafil—Immune system disorder—Epirubicin—pancreatic cancer	0.000255	0.000673	CcSEcCtD
Vardenafil—Mediastinal disorder—Epirubicin—pancreatic cancer	0.000254	0.000672	CcSEcCtD
Vardenafil—Pain—Docetaxel—pancreatic cancer	0.000254	0.000672	CcSEcCtD
Vardenafil—Visual impairment—Doxorubicin—pancreatic cancer	0.000252	0.000665	CcSEcCtD
Vardenafil—Nausea—Gemcitabine—pancreatic cancer	0.000249	0.000657	CcSEcCtD
Vardenafil—Mental disorder—Epirubicin—pancreatic cancer	0.000247	0.000653	CcSEcCtD
Vardenafil—Erythema—Epirubicin—pancreatic cancer	0.000246	0.000649	CcSEcCtD
Vardenafil—Feeling abnormal—Docetaxel—pancreatic cancer	0.000245	0.000647	CcSEcCtD
Vardenafil—Nausea—Fluorouracil—pancreatic cancer	0.000245	0.000646	CcSEcCtD
Vardenafil—Eye disorder—Doxorubicin—pancreatic cancer	0.000244	0.000645	CcSEcCtD
Vardenafil—Tinnitus—Doxorubicin—pancreatic cancer	0.000243	0.000643	CcSEcCtD
Vardenafil—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.000243	0.000642	CcSEcCtD
Vardenafil—Cardiac disorder—Doxorubicin—pancreatic cancer	0.000242	0.00064	CcSEcCtD
Vardenafil—Flushing—Doxorubicin—pancreatic cancer	0.000242	0.00064	CcSEcCtD
Vardenafil—Back pain—Epirubicin—pancreatic cancer	0.000238	0.000628	CcSEcCtD
Vardenafil—Angiopathy—Doxorubicin—pancreatic cancer	0.000237	0.000626	CcSEcCtD
Vardenafil—Muscle spasms—Epirubicin—pancreatic cancer	0.000236	0.000624	CcSEcCtD
Vardenafil—Immune system disorder—Doxorubicin—pancreatic cancer	0.000236	0.000623	CcSEcCtD
Vardenafil—Mediastinal disorder—Doxorubicin—pancreatic cancer	0.000235	0.000622	CcSEcCtD
Vardenafil—Abdominal pain—Docetaxel—pancreatic cancer	0.000235	0.000621	CcSEcCtD
Vardenafil—Vision blurred—Epirubicin—pancreatic cancer	0.000232	0.000612	CcSEcCtD
Vardenafil—Mental disorder—Doxorubicin—pancreatic cancer	0.000229	0.000604	CcSEcCtD
Vardenafil—Ill-defined disorder—Epirubicin—pancreatic cancer	0.000228	0.000602	CcSEcCtD
Vardenafil—Erythema—Doxorubicin—pancreatic cancer	0.000227	0.0006	CcSEcCtD
Vardenafil—Malaise—Epirubicin—pancreatic cancer	0.000222	0.000585	CcSEcCtD
Vardenafil—Vertigo—Epirubicin—pancreatic cancer	0.000221	0.000583	CcSEcCtD
Vardenafil—Syncope—Epirubicin—pancreatic cancer	0.00022	0.000582	CcSEcCtD
Vardenafil—Back pain—Doxorubicin—pancreatic cancer	0.00022	0.000581	CcSEcCtD
Vardenafil—Hypersensitivity—Docetaxel—pancreatic cancer	0.000219	0.000579	CcSEcCtD
Vardenafil—Muscle spasms—Doxorubicin—pancreatic cancer	0.000219	0.000577	CcSEcCtD
Vardenafil—Palpitations—Epirubicin—pancreatic cancer	0.000217	0.000574	CcSEcCtD
Vardenafil—Loss of consciousness—Epirubicin—pancreatic cancer	0.000216	0.00057	CcSEcCtD
Vardenafil—Vision blurred—Doxorubicin—pancreatic cancer	0.000214	0.000566	CcSEcCtD
Vardenafil—Asthenia—Docetaxel—pancreatic cancer	0.000213	0.000563	CcSEcCtD
Vardenafil—Convulsion—Epirubicin—pancreatic cancer	0.000213	0.000562	CcSEcCtD
Vardenafil—Ill-defined disorder—Doxorubicin—pancreatic cancer	0.000211	0.000557	CcSEcCtD
Vardenafil—Pruritus—Docetaxel—pancreatic cancer	0.00021	0.000556	CcSEcCtD
Vardenafil—Myalgia—Epirubicin—pancreatic cancer	0.000209	0.000553	CcSEcCtD
Vardenafil—Arthralgia—Epirubicin—pancreatic cancer	0.000209	0.000553	CcSEcCtD
Vardenafil—Chest pain—Epirubicin—pancreatic cancer	0.000209	0.000553	CcSEcCtD
Vardenafil—Anxiety—Epirubicin—pancreatic cancer	0.000208	0.000551	CcSEcCtD
Vardenafil—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	0.000208	0.000549	CcSEcCtD
Vardenafil—Discomfort—Epirubicin—pancreatic cancer	0.000207	0.000546	CcSEcCtD
Vardenafil—Malaise—Doxorubicin—pancreatic cancer	0.000205	0.000542	CcSEcCtD
Vardenafil—Dry mouth—Epirubicin—pancreatic cancer	0.000205	0.00054	CcSEcCtD
Vardenafil—Vertigo—Doxorubicin—pancreatic cancer	0.000204	0.00054	CcSEcCtD
Vardenafil—Syncope—Doxorubicin—pancreatic cancer	0.000204	0.000539	CcSEcCtD
Vardenafil—Diarrhoea—Docetaxel—pancreatic cancer	0.000203	0.000537	CcSEcCtD
Vardenafil—Palpitations—Doxorubicin—pancreatic cancer	0.000201	0.000531	CcSEcCtD
Vardenafil—Anaphylactic shock—Epirubicin—pancreatic cancer	0.000201	0.00053	CcSEcCtD
Vardenafil—Loss of consciousness—Doxorubicin—pancreatic cancer	0.0002	0.000528	CcSEcCtD
Vardenafil—Infection—Epirubicin—pancreatic cancer	0.000199	0.000526	CcSEcCtD
Vardenafil—Shock—Epirubicin—pancreatic cancer	0.000197	0.000521	CcSEcCtD
Vardenafil—Convulsion—Doxorubicin—pancreatic cancer	0.000197	0.00052	CcSEcCtD
Vardenafil—Nervous system disorder—Epirubicin—pancreatic cancer	0.000197	0.000519	CcSEcCtD
Vardenafil—Dizziness—Docetaxel—pancreatic cancer	0.000197	0.000519	CcSEcCtD
Vardenafil—Tachycardia—Epirubicin—pancreatic cancer	0.000196	0.000517	CcSEcCtD
Vardenafil—Skin disorder—Epirubicin—pancreatic cancer	0.000195	0.000514	CcSEcCtD
Vardenafil—Hyperhidrosis—Epirubicin—pancreatic cancer	0.000194	0.000512	CcSEcCtD
Vardenafil—Myalgia—Doxorubicin—pancreatic cancer	0.000194	0.000511	CcSEcCtD
Vardenafil—Chest pain—Doxorubicin—pancreatic cancer	0.000194	0.000511	CcSEcCtD
Vardenafil—Arthralgia—Doxorubicin—pancreatic cancer	0.000194	0.000511	CcSEcCtD
Vardenafil—Anxiety—Doxorubicin—pancreatic cancer	0.000193	0.000509	CcSEcCtD
Vardenafil—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	0.000192	0.000508	CcSEcCtD
Vardenafil—Discomfort—Doxorubicin—pancreatic cancer	0.000191	0.000505	CcSEcCtD
Vardenafil—Dry mouth—Doxorubicin—pancreatic cancer	0.000189	0.0005	CcSEcCtD
Vardenafil—Vomiting—Docetaxel—pancreatic cancer	0.000189	0.000499	CcSEcCtD
Vardenafil—Rash—Docetaxel—pancreatic cancer	0.000187	0.000495	CcSEcCtD
Vardenafil—Hypotension—Epirubicin—pancreatic cancer	0.000187	0.000495	CcSEcCtD
Vardenafil—Dermatitis—Docetaxel—pancreatic cancer	0.000187	0.000495	CcSEcCtD
Vardenafil—Headache—Docetaxel—pancreatic cancer	0.000186	0.000492	CcSEcCtD
Vardenafil—Anaphylactic shock—Doxorubicin—pancreatic cancer	0.000186	0.00049	CcSEcCtD
Vardenafil—Infection—Doxorubicin—pancreatic cancer	0.000184	0.000487	CcSEcCtD
Vardenafil—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	0.000183	0.000483	CcSEcCtD
Vardenafil—Shock—Doxorubicin—pancreatic cancer	0.000183	0.000482	CcSEcCtD
Vardenafil—Nervous system disorder—Doxorubicin—pancreatic cancer	0.000182	0.000481	CcSEcCtD
Vardenafil—Insomnia—Epirubicin—pancreatic cancer	0.000181	0.000479	CcSEcCtD
Vardenafil—Tachycardia—Doxorubicin—pancreatic cancer	0.000181	0.000478	CcSEcCtD
Vardenafil—Skin disorder—Doxorubicin—pancreatic cancer	0.00018	0.000476	CcSEcCtD
Vardenafil—Paraesthesia—Epirubicin—pancreatic cancer	0.00018	0.000476	CcSEcCtD
Vardenafil—Hyperhidrosis—Doxorubicin—pancreatic cancer	0.000179	0.000474	CcSEcCtD
Vardenafil—Dyspnoea—Epirubicin—pancreatic cancer	0.000179	0.000472	CcSEcCtD
Vardenafil—Somnolence—Epirubicin—pancreatic cancer	0.000178	0.000471	CcSEcCtD
Vardenafil—Nausea—Docetaxel—pancreatic cancer	0.000177	0.000466	CcSEcCtD
Vardenafil—Dyspepsia—Epirubicin—pancreatic cancer	0.000176	0.000466	CcSEcCtD
Vardenafil—Hypotension—Doxorubicin—pancreatic cancer	0.000173	0.000458	CcSEcCtD
Vardenafil—Gastrointestinal disorder—Epirubicin—pancreatic cancer	0.000173	0.000457	CcSEcCtD
Vardenafil—Pain—Epirubicin—pancreatic cancer	0.000171	0.000453	CcSEcCtD
Vardenafil—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	0.000169	0.000447	CcSEcCtD
Vardenafil—Insomnia—Doxorubicin—pancreatic cancer	0.000168	0.000443	CcSEcCtD
Vardenafil—Paraesthesia—Doxorubicin—pancreatic cancer	0.000167	0.00044	CcSEcCtD
Vardenafil—Dyspnoea—Doxorubicin—pancreatic cancer	0.000165	0.000437	CcSEcCtD
Vardenafil—Feeling abnormal—Epirubicin—pancreatic cancer	0.000165	0.000436	CcSEcCtD
Vardenafil—Somnolence—Doxorubicin—pancreatic cancer	0.000165	0.000436	CcSEcCtD
Vardenafil—Gastrointestinal pain—Epirubicin—pancreatic cancer	0.000164	0.000433	CcSEcCtD
Vardenafil—Dyspepsia—Doxorubicin—pancreatic cancer	0.000163	0.000431	CcSEcCtD
Vardenafil—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	0.00016	0.000423	CcSEcCtD
Vardenafil—Pain—Doxorubicin—pancreatic cancer	0.000159	0.000419	CcSEcCtD
Vardenafil—Abdominal pain—Epirubicin—pancreatic cancer	0.000159	0.000419	CcSEcCtD
Vardenafil—Feeling abnormal—Doxorubicin—pancreatic cancer	0.000153	0.000404	CcSEcCtD
Vardenafil—Gastrointestinal pain—Doxorubicin—pancreatic cancer	0.000152	0.000401	CcSEcCtD
Vardenafil—Hypersensitivity—Epirubicin—pancreatic cancer	0.000148	0.00039	CcSEcCtD
Vardenafil—Abdominal pain—Doxorubicin—pancreatic cancer	0.000147	0.000387	CcSEcCtD
Vardenafil—Asthenia—Epirubicin—pancreatic cancer	0.000144	0.00038	CcSEcCtD
Vardenafil—Pruritus—Epirubicin—pancreatic cancer	0.000142	0.000375	CcSEcCtD
Vardenafil—Diarrhoea—Epirubicin—pancreatic cancer	0.000137	0.000362	CcSEcCtD
Vardenafil—Hypersensitivity—Doxorubicin—pancreatic cancer	0.000137	0.000361	CcSEcCtD
Vardenafil—Asthenia—Doxorubicin—pancreatic cancer	0.000133	0.000352	CcSEcCtD
Vardenafil—Dizziness—Epirubicin—pancreatic cancer	0.000133	0.00035	CcSEcCtD
Vardenafil—Pruritus—Doxorubicin—pancreatic cancer	0.000131	0.000347	CcSEcCtD
Vardenafil—Vomiting—Epirubicin—pancreatic cancer	0.000127	0.000337	CcSEcCtD
Vardenafil—Diarrhoea—Doxorubicin—pancreatic cancer	0.000127	0.000335	CcSEcCtD
Vardenafil—Rash—Epirubicin—pancreatic cancer	0.000126	0.000334	CcSEcCtD
Vardenafil—Dermatitis—Epirubicin—pancreatic cancer	0.000126	0.000334	CcSEcCtD
Vardenafil—Headache—Epirubicin—pancreatic cancer	0.000126	0.000332	CcSEcCtD
Vardenafil—Dizziness—Doxorubicin—pancreatic cancer	0.000123	0.000324	CcSEcCtD
Vardenafil—Nausea—Epirubicin—pancreatic cancer	0.000119	0.000315	CcSEcCtD
Vardenafil—Vomiting—Doxorubicin—pancreatic cancer	0.000118	0.000312	CcSEcCtD
Vardenafil—Rash—Doxorubicin—pancreatic cancer	0.000117	0.000309	CcSEcCtD
Vardenafil—Dermatitis—Doxorubicin—pancreatic cancer	0.000117	0.000309	CcSEcCtD
Vardenafil—Headache—Doxorubicin—pancreatic cancer	0.000116	0.000307	CcSEcCtD
Vardenafil—Nausea—Doxorubicin—pancreatic cancer	0.00011	0.000291	CcSEcCtD
Vardenafil—PDE6G—Signaling Pathways—NFKBIA—pancreatic cancer	8.28e-05	0.000471	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—NOTCH1—pancreatic cancer	8.2e-05	0.000467	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—PTHLH—pancreatic cancer	8.19e-05	0.000466	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—PTCH1—pancreatic cancer	8.19e-05	0.000466	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—NFKBIA—pancreatic cancer	8.07e-05	0.000459	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—PIK3CB—pancreatic cancer	8.06e-05	0.000459	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—PIK3CG—pancreatic cancer	8.02e-05	0.000456	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—NOTCH1—pancreatic cancer	7.99e-05	0.000455	CbGpPWpGaD
Vardenafil—PDE11A—Signaling by GPCR—EGFR—pancreatic cancer	7.99e-05	0.000455	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by NGF—HRAS—pancreatic cancer	7.97e-05	0.000454	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—EGF—pancreatic cancer	7.93e-05	0.000451	CbGpPWpGaD
Vardenafil—PDE1B—Disease—SMAD4—pancreatic cancer	7.85e-05	0.000447	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—PIK3CG—pancreatic cancer	7.82e-05	0.000445	CbGpPWpGaD
Vardenafil—PDE10A—Signaling by GPCR—NRAS—pancreatic cancer	7.82e-05	0.000445	CbGpPWpGaD
Vardenafil—PDE6G—Disease—CTNNB1—pancreatic cancer	7.78e-05	0.000443	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—EGF—pancreatic cancer	7.73e-05	0.00044	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—PIK3CD—pancreatic cancer	7.71e-05	0.000439	CbGpPWpGaD
Vardenafil—PDE1B—Disease—HES1—pancreatic cancer	7.66e-05	0.000436	CbGpPWpGaD
Vardenafil—PDE11A—GPCR downstream signaling—PIK3CA—pancreatic cancer	7.64e-05	0.000435	CbGpPWpGaD
Vardenafil—PDE6G—Disease—PTEN—pancreatic cancer	7.58e-05	0.000432	CbGpPWpGaD
Vardenafil—PDE11A—Signaling by GPCR—KRAS—pancreatic cancer	7.55e-05	0.000429	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—PRSS1—pancreatic cancer	7.51e-05	0.000427	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—SST—pancreatic cancer	7.49e-05	0.000426	CbGpPWpGaD
Vardenafil—PDE1B—GPCR downstream signaling—PIK3CG—pancreatic cancer	7.39e-05	0.00042	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—JAG1—pancreatic cancer	7.33e-05	0.000417	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—NOTCH3—pancreatic cancer	7.3e-05	0.000415	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—SRC—pancreatic cancer	7.18e-05	0.000408	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—CTNNB1—pancreatic cancer	7.15e-05	0.000407	CbGpPWpGaD
Vardenafil—PDE10A—Signaling by GPCR—EGFR—pancreatic cancer	7.12e-05	0.000405	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—PIK3CD—pancreatic cancer	7.05e-05	0.000401	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by NGF—AKT1—pancreatic cancer	7.04e-05	0.0004	CbGpPWpGaD
Vardenafil—PDE6G—Disease—SRC—pancreatic cancer	7.03e-05	0.0004	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—VEGFA—pancreatic cancer	6.99e-05	0.000398	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—BCL2L1—pancreatic cancer	6.98e-05	0.000397	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—PTEN—pancreatic cancer	6.97e-05	0.000396	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—TSC2—pancreatic cancer	6.94e-05	0.000395	CbGpPWpGaD
Vardenafil—PDE11A—Signaling by GPCR—PIK3CA—pancreatic cancer	6.94e-05	0.000395	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—CNR1—pancreatic cancer	6.91e-05	0.000393	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—NRAS—pancreatic cancer	6.9e-05	0.000393	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—PIK3CD—pancreatic cancer	6.87e-05	0.000391	CbGpPWpGaD
Vardenafil—PDE10A—GPCR downstream signaling—PIK3CA—pancreatic cancer	6.81e-05	0.000387	CbGpPWpGaD
Vardenafil—PDE6G—Disease—STAT3—pancreatic cancer	6.78e-05	0.000386	CbGpPWpGaD
Vardenafil—PDE6G—Disease—NRAS—pancreatic cancer	6.77e-05	0.000385	CbGpPWpGaD
Vardenafil—PDE10A—Signaling by GPCR—KRAS—pancreatic cancer	6.73e-05	0.000383	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—PIK3CB—pancreatic cancer	6.72e-05	0.000382	CbGpPWpGaD
Vardenafil—PDE1B—Disease—TERT—pancreatic cancer	6.71e-05	0.000382	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—PIK3CG—pancreatic cancer	6.71e-05	0.000382	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—GCG—pancreatic cancer	6.67e-05	0.00038	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—ARG2—pancreatic cancer	6.51e-05	0.00037	CbGpPWpGaD
Vardenafil—PDE1B—GPCR downstream signaling—PIK3CD—pancreatic cancer	6.49e-05	0.000369	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—SRC—pancreatic cancer	6.46e-05	0.000368	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—CXCL8—pancreatic cancer	6.46e-05	0.000367	CbGpPWpGaD
Vardenafil—PDE1B—Disease—HIF1A—pancreatic cancer	6.42e-05	0.000365	CbGpPWpGaD
Vardenafil—PDE11A—Signaling by GPCR—HRAS—pancreatic cancer	6.42e-05	0.000365	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—TGFB1—pancreatic cancer	6.41e-05	0.000365	CbGpPWpGaD
Vardenafil—PDE1B—Disease—TSC2—pancreatic cancer	6.41e-05	0.000364	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—AGTR1—pancreatic cancer	6.37e-05	0.000362	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—NFKBIA—pancreatic cancer	6.33e-05	0.00036	CbGpPWpGaD
Vardenafil—PDE6G—Disease—MYC—pancreatic cancer	6.3e-05	0.000359	CbGpPWpGaD
Vardenafil—PDE6G—Disease—TGFB1—pancreatic cancer	6.29e-05	0.000358	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—STK11—pancreatic cancer	6.27e-05	0.000357	CbGpPWpGaD
Vardenafil—PDE1B—Disease—APOE—pancreatic cancer	6.27e-05	0.000357	CbGpPWpGaD
Vardenafil—PDE11A—GPCR downstream signaling—AKT1—pancreatic cancer	6.24e-05	0.000355	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—NRAS—pancreatic cancer	6.21e-05	0.000354	CbGpPWpGaD
Vardenafil—PDE10A—Signaling by GPCR—PIK3CA—pancreatic cancer	6.18e-05	0.000352	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—CASP3—pancreatic cancer	6.18e-05	0.000352	CbGpPWpGaD
Vardenafil—PDE6G—Disease—EGFR—pancreatic cancer	6.17e-05	0.000351	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—PIK3CB—pancreatic cancer	6.15e-05	0.00035	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—EGF—pancreatic cancer	6.06e-05	0.000345	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—CCND1—pancreatic cancer	6.02e-05	0.000342	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—PIK3CB—pancreatic cancer	5.99e-05	0.000341	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—CTNNB1—pancreatic cancer	5.96e-05	0.000339	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—KRAS—pancreatic cancer	5.94e-05	0.000338	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—CXCL8—pancreatic cancer	5.91e-05	0.000336	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—PIK3CD—pancreatic cancer	5.9e-05	0.000335	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—MMP9—pancreatic cancer	5.84e-05	0.000332	CbGpPWpGaD
Vardenafil—PDE6G—Disease—KRAS—pancreatic cancer	5.82e-05	0.000331	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—PTEN—pancreatic cancer	5.81e-05	0.00033	CbGpPWpGaD
Vardenafil—PDE1B—Disease—NOTCH1—pancreatic cancer	5.79e-05	0.000329	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—CXCL8—pancreatic cancer	5.76e-05	0.000328	CbGpPWpGaD
Vardenafil—PDE10A—Signaling by GPCR—HRAS—pancreatic cancer	5.72e-05	0.000325	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—TYMP—pancreatic cancer	5.69e-05	0.000324	CbGpPWpGaD
Vardenafil—PDE11A—Signaling by GPCR—AKT1—pancreatic cancer	5.67e-05	0.000322	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—EGFR—pancreatic cancer	5.66e-05	0.000322	CbGpPWpGaD
Vardenafil—PDE1B—GPCR downstream signaling—PIK3CB—pancreatic cancer	5.66e-05	0.000322	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—CASP3—pancreatic cancer	5.65e-05	0.000322	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—CDH1—pancreatic cancer	5.64e-05	0.000321	CbGpPWpGaD
Vardenafil—PDE1B—Disease—EGF—pancreatic cancer	5.59e-05	0.000318	CbGpPWpGaD
Vardenafil—PDE10A—GPCR downstream signaling—AKT1—pancreatic cancer	5.56e-05	0.000316	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—CASP3—pancreatic cancer	5.51e-05	0.000313	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—CCND1—pancreatic cancer	5.5e-05	0.000313	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—SMAD4—pancreatic cancer	5.5e-05	0.000313	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—PIK3CA—pancreatic cancer	5.46e-05	0.000311	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—CTNNB1—pancreatic cancer	5.45e-05	0.00031	CbGpPWpGaD
Vardenafil—PDE1B—GPCR downstream signaling—CXCL8—pancreatic cancer	5.44e-05	0.000309	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—PIK3CD—pancreatic cancer	5.39e-05	0.000306	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—SRC—pancreatic cancer	5.39e-05	0.000306	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—HES1—pancreatic cancer	5.37e-05	0.000305	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—CCND1—pancreatic cancer	5.36e-05	0.000305	CbGpPWpGaD
Vardenafil—PDE6G—Disease—PIK3CA—pancreatic cancer	5.35e-05	0.000304	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—KRAS—pancreatic cancer	5.35e-05	0.000304	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—MMP9—pancreatic cancer	5.34e-05	0.000304	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—PTEN—pancreatic cancer	5.31e-05	0.000302	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—CTNNB1—pancreatic cancer	5.31e-05	0.000302	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—TP53—pancreatic cancer	5.28e-05	0.0003	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—VEGFA—pancreatic cancer	5.25e-05	0.000298	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—MMP9—pancreatic cancer	5.21e-05	0.000296	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—STAT3—pancreatic cancer	5.19e-05	0.000295	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—NRAS—pancreatic cancer	5.18e-05	0.000295	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—PTEN—pancreatic cancer	5.18e-05	0.000294	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—PIK3CB—pancreatic cancer	5.14e-05	0.000292	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—HRAS—pancreatic cancer	5.05e-05	0.000287	CbGpPWpGaD
Vardenafil—PDE10A—Signaling by GPCR—AKT1—pancreatic cancer	5.05e-05	0.000287	CbGpPWpGaD
Vardenafil—PDE1B—Disease—PIK3CD—pancreatic cancer	4.97e-05	0.000283	CbGpPWpGaD
Vardenafil—PDE6G—Disease—HRAS—pancreatic cancer	4.95e-05	0.000282	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—CXCL8—pancreatic cancer	4.94e-05	0.000281	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—SRC—pancreatic cancer	4.93e-05	0.00028	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—PIK3CA—pancreatic cancer	4.91e-05	0.00028	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—MYC—pancreatic cancer	4.83e-05	0.000275	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—TGFB1—pancreatic cancer	4.81e-05	0.000274	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—SRC—pancreatic cancer	4.8e-05	0.000273	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—VEGFA—pancreatic cancer	4.8e-05	0.000273	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—STAT3—pancreatic cancer	4.75e-05	0.00027	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—NRAS—pancreatic cancer	4.74e-05	0.00027	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—EGFR—pancreatic cancer	4.72e-05	0.000269	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—TERT—pancreatic cancer	4.7e-05	0.000268	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—PIK3CB—pancreatic cancer	4.7e-05	0.000267	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—VEGFA—pancreatic cancer	4.68e-05	0.000266	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—STAT3—pancreatic cancer	4.63e-05	0.000263	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—NRAS—pancreatic cancer	4.62e-05	0.000263	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—GLP1R—pancreatic cancer	4.59e-05	0.000261	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—HRAS—pancreatic cancer	4.55e-05	0.000259	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—DPYD—pancreatic cancer	4.51e-05	0.000257	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—HIF1A—pancreatic cancer	4.5e-05	0.000256	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—TSC2—pancreatic cancer	4.49e-05	0.000255	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—AKT1—pancreatic cancer	4.46e-05	0.000254	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—KRAS—pancreatic cancer	4.46e-05	0.000254	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—MYC—pancreatic cancer	4.41e-05	0.000251	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—TGFB1—pancreatic cancer	4.4e-05	0.000251	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—APOE—pancreatic cancer	4.39e-05	0.00025	CbGpPWpGaD
Vardenafil—PDE6G—Disease—AKT1—pancreatic cancer	4.37e-05	0.000249	CbGpPWpGaD
Vardenafil—PDE1B—Disease—PIK3CB—pancreatic cancer	4.34e-05	0.000247	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—EGFR—pancreatic cancer	4.32e-05	0.000246	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—MYC—pancreatic cancer	4.3e-05	0.000245	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—KDR—pancreatic cancer	4.3e-05	0.000245	CbGpPWpGaD
Vardenafil—PDE1B—Disease—PTGS2—pancreatic cancer	4.3e-05	0.000244	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—TGFB1—pancreatic cancer	4.29e-05	0.000244	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—SLC2A2—pancreatic cancer	4.28e-05	0.000244	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—EGFR—pancreatic cancer	4.21e-05	0.000239	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—CTNNB1—pancreatic cancer	4.16e-05	0.000237	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—PIK3CA—pancreatic cancer	4.1e-05	0.000233	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—NFKBIA—pancreatic cancer	4.09e-05	0.000233	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—KRAS—pancreatic cancer	4.08e-05	0.000232	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—PTEN—pancreatic cancer	4.06e-05	0.000231	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—NOTCH1—pancreatic cancer	4.05e-05	0.000231	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—AKT1—pancreatic cancer	4.01e-05	0.000228	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—KRAS—pancreatic cancer	3.97e-05	0.000226	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—TP53—pancreatic cancer	3.96e-05	0.000225	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—PIK3CG—pancreatic cancer	3.96e-05	0.000225	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—NRAS—pancreatic cancer	3.96e-05	0.000225	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—EGF—pancreatic cancer	3.92e-05	0.000223	CbGpPWpGaD
Vardenafil—PDE1B—Disease—CTNNB1—pancreatic cancer	3.84e-05	0.000219	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—HRAS—pancreatic cancer	3.79e-05	0.000216	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—SRC—pancreatic cancer	3.76e-05	0.000214	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—PIK3CA—pancreatic cancer	3.75e-05	0.000213	CbGpPWpGaD
Vardenafil—PDE1B—Disease—PTEN—pancreatic cancer	3.75e-05	0.000213	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—PIK3CA—pancreatic cancer	3.65e-05	0.000208	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—STAT3—pancreatic cancer	3.63e-05	0.000206	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—TP53—pancreatic cancer	3.62e-05	0.000206	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—NRAS—pancreatic cancer	3.62e-05	0.000206	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—EGFR—pancreatic cancer	3.61e-05	0.000205	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—TP53—pancreatic cancer	3.53e-05	0.000201	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—PRSS1—pancreatic cancer	3.49e-05	0.000199	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—PIK3CD—pancreatic cancer	3.48e-05	0.000198	CbGpPWpGaD
Vardenafil—PDE1B—Disease—SRC—pancreatic cancer	3.47e-05	0.000198	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—HRAS—pancreatic cancer	3.47e-05	0.000197	CbGpPWpGaD
Vardenafil—PDE1B—GPCR downstream signaling—PIK3CA—pancreatic cancer	3.45e-05	0.000196	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—KRAS—pancreatic cancer	3.41e-05	0.000194	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—HRAS—pancreatic cancer	3.38e-05	0.000192	CbGpPWpGaD
Vardenafil—PDE1B—Disease—STAT3—pancreatic cancer	3.35e-05	0.000191	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—AKT1—pancreatic cancer	3.35e-05	0.00019	CbGpPWpGaD
Vardenafil—PDE1B—Disease—NRAS—pancreatic cancer	3.34e-05	0.00019	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—CD44—pancreatic cancer	3.32e-05	0.000189	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—EGFR—pancreatic cancer	3.3e-05	0.000188	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—GCG—pancreatic cancer	3.18e-05	0.000181	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—PIK3CA—pancreatic cancer	3.13e-05	0.000178	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—KRAS—pancreatic cancer	3.12e-05	0.000177	CbGpPWpGaD
Vardenafil—PDE1B—Disease—MYC—pancreatic cancer	3.11e-05	0.000177	CbGpPWpGaD
Vardenafil—PDE1B—Disease—TGFB1—pancreatic cancer	3.11e-05	0.000177	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—AKT1—pancreatic cancer	3.06e-05	0.000174	CbGpPWpGaD
Vardenafil—PDE1B—Disease—EGFR—pancreatic cancer	3.04e-05	0.000173	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—PIK3CB—pancreatic cancer	3.04e-05	0.000173	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—ARG2—pancreatic cancer	3.03e-05	0.000172	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—STK11—pancreatic cancer	2.99e-05	0.00017	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—AKT1—pancreatic cancer	2.98e-05	0.00017	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—CXCL8—pancreatic cancer	2.92e-05	0.000166	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—HRAS—pancreatic cancer	2.9e-05	0.000165	CbGpPWpGaD
Vardenafil—PDE1B—Disease—KRAS—pancreatic cancer	2.88e-05	0.000164	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—PIK3CA—pancreatic cancer	2.86e-05	0.000163	CbGpPWpGaD
Vardenafil—PDE1B—GPCR downstream signaling—AKT1—pancreatic cancer	2.82e-05	0.00016	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—CASP3—pancreatic cancer	2.79e-05	0.000159	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—CCND1—pancreatic cancer	2.72e-05	0.000155	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—CTNNB1—pancreatic cancer	2.69e-05	0.000153	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—HRAS—pancreatic cancer	2.65e-05	0.000151	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—TYMP—pancreatic cancer	2.64e-05	0.00015	CbGpPWpGaD
Vardenafil—PDE1B—Disease—PIK3CA—pancreatic cancer	2.64e-05	0.00015	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—MMP9—pancreatic cancer	2.64e-05	0.00015	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—PTEN—pancreatic cancer	2.62e-05	0.000149	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—TYMS—pancreatic cancer	2.57e-05	0.000146	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—AKT1—pancreatic cancer	2.56e-05	0.000146	CbGpPWpGaD
Vardenafil—PDE1B—Disease—HRAS—pancreatic cancer	2.44e-05	0.000139	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—SRC—pancreatic cancer	2.43e-05	0.000138	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—VEGFA—pancreatic cancer	2.37e-05	0.000135	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—STAT3—pancreatic cancer	2.35e-05	0.000133	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—NRAS—pancreatic cancer	2.34e-05	0.000133	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—AKT1—pancreatic cancer	2.34e-05	0.000133	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—MYC—pancreatic cancer	2.18e-05	0.000124	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—TGFB1—pancreatic cancer	2.17e-05	0.000124	CbGpPWpGaD
Vardenafil—PDE1B—Disease—AKT1—pancreatic cancer	2.16e-05	0.000123	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—EGFR—pancreatic cancer	2.13e-05	0.000121	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—GLP1R—pancreatic cancer	2.13e-05	0.000121	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—DPYD—pancreatic cancer	2.1e-05	0.000119	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—APOE—pancreatic cancer	2.09e-05	0.000119	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—KRAS—pancreatic cancer	2.01e-05	0.000115	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—SLC2A2—pancreatic cancer	1.99e-05	0.000113	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—PIK3CG—pancreatic cancer	1.89e-05	0.000107	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—PIK3CA—pancreatic cancer	1.85e-05	0.000105	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—PPARG—pancreatic cancer	1.82e-05	0.000104	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—TP53—pancreatic cancer	1.79e-05	0.000102	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—HRAS—pancreatic cancer	1.71e-05	9.74e-05	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—PIK3CD—pancreatic cancer	1.66e-05	9.44e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—CD44—pancreatic cancer	1.54e-05	8.77e-05	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—AKT1—pancreatic cancer	1.51e-05	8.6e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—GCG—pancreatic cancer	1.48e-05	8.41e-05	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—PIK3CB—pancreatic cancer	1.45e-05	8.23e-05	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—PTGS2—pancreatic cancer	1.43e-05	8.15e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—STK11—pancreatic cancer	1.39e-05	7.9e-05	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—PTEN—pancreatic cancer	1.25e-05	7.11e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—TYMS—pancreatic cancer	1.2e-05	6.8e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—APOE—pancreatic cancer	9.72e-06	5.53e-05	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—PIK3CA—pancreatic cancer	8.81e-06	5.01e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	8.77e-06	4.99e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—PPARG—pancreatic cancer	8.47e-06	4.82e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	7.71e-06	4.39e-05	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—AKT1—pancreatic cancer	7.2e-06	4.1e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	6.72e-06	3.82e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—PTGS2—pancreatic cancer	6.66e-06	3.79e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—PTEN—pancreatic cancer	5.81e-06	3.3e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	4.1e-06	2.33e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—AKT1—pancreatic cancer	3.35e-06	1.9e-05	CbGpPWpGaD
